Transport of flavonoids into the brain

Micronutrients and Brain Health

Volumn , Issue , 2009, Pages 265-279

  Milbury, Paul E ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057673954     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Williamson, G., and Manach, C., Bioavailability and bioefficacy of polyphenols in humans: II. Review of 93 intervention studies. Am. J. Clin. Nutr., 81, 243S, 2005.
2. Middleton, E., Jr., Kandaswami, C., and Theoharides, T. C., The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev., 52, 673, 2000.
3. Harborne, J. B., and Williams, C. A., Advances in flavonoid research since 1992. Phytochemistry, 55, 481, 2000.
4. Dajas, F., et al., Neuroprotection by flavonoids. Braz. J. Med. Biol. Res., 36, 1613, 2003.
5. Dajas, F., et al., Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotoxicity Res., 5, 425, 2003.
6. Bailey, D. G., et al., Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med., 12, 357, 1989.
7. Saito, M., et al., Undesirable effects of citrus juice on the pharmacokinetics of drugs: Focus on recent studies. Drug Saf., 28, 677, 2005.
8. Zhang, S., and Morris, M. E., Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258, 2003.
9. Kitagawa, S., Nabekura, T., and Kamiyama, S., Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 56, 1001, 2004.
10. Fuchikami, H., et al., Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 34, 577, 2006.
11. Wu, C.-P., et al., Modulatory effects of plant phenols on human multidrug resistance proteins 1, 4, and 5 (ABCC1, 4 and 5). FEBS J., 272, 4725, 2005.
12. Vaidyanathan, J. B., and Walle, T., Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res., 18, 1420, 2001.
13. Mandel, S., et al., Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotoxicity Res., 5, 419, 2003.
14. Youdim, K. A., et al., Interaction between flavonoids and the blood-brain barrier: In vitro studies. J. Neurochem., 85, 180, 2003.
15. Walle, T., Absorption and metabolism of flavonoids. Free Radic. Biol. Med., 36, 829, 2004.
16. Manach, C., and Donovan, J. L., Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic. Res., 38, 771, 2004.
17. Hollman, P. C., et al., The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic. Res., 31, 569, 1999.
18. Rios, L., et al., Cocoa proanthocyanidins are stable during gastric transit in humans. Am. J. Clin. Nutr., 76, 1106, 2002.
19. Sesink, A. L., et al., Intestinal uptake of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin hydrolase. J. Nutr., 133, 773, 2003.
20. Day, A. J., et al., Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett., 468, 166, 2000.
21. Ioku, K., et al., Glucosidase activity in the rat small intestine toward quercetin monoglucosides. Biosci. Biotechnol. Biochem., 62, 1428, 1998.
22. Day, A. J., et al., Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett., 436, 71, 1998.
23. Nemeth, K., et al., Deglycosylation by small intestinal epithelial cell β-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr., 42, 29, 2003.
24. Walle, T., et al., Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J. Nutr., 135, 48, 2005.
25. Browning, A. M., Walle, U. K., and Walle, T., Flavonoid glycosides inhibit oral cancer cell proliferation -Role of cellular uptake and hydrolysis to the aglycones. J. Pharm. Pharmacol., 57, 1037, 2005.
26. Crespy, V., et al., Quercetin, but not its glycosides, is absorbed from the rat stomach. J. Agric. Food. Chem., 50, 618, 2002.
27. Hollman, P. C. H., et al., Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr., 62, 1276, 1995.
28. Walgren, R. A., et al., Cellular uptake of dietary flavonoid quercetin 4′-β-glucoside by sodium-dependent glucose transporter SGLT1. J. Pharmacol. Exp. Ther., 294, 837, 2000.
29. Wolffram, S., Blöck, M., and Ader, P., Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J. Nutr., 132, 630, 2002.
30. Walton, M. C., et al., The flavonol quercetin-3-glucoside inhibits cyanidin-3-glucoside absorption in vitro. J. Agric. Food Chem., 54, 4913, 2006.
31. Crespy, V., et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am. J. Physiol., 277, G120, 1999.
32. Karakaya, S., Bioavailability of phenolic compounds. Crit. Rev. Food Sci. Nutr., 44, 453, 2004.
33. Lu, H., Meng, X., and Yang, C. S., Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (2)-epigallocatechin gallate. Drug Metab. Disp., 31, 572, 2003.
34. Walgren, R. A., et al., Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J. Pharmacol. Exp. Ther., 294, 830, 2000.
35. Van der Woude, H., et al., Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems. Chem. Res. Toxicol., 17, 1520, 2004.
36. Aird, W. C., Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ. Res., 100, 158, 2007.
37. Ueno, M., et al., Blood-brain barrier permeability in the periventricular areas of the normal mouse brain. Acta Neuropathol., 99, 385, 2000.
38. Pollay, M., and Roberts, P. A., Blood-brain barrier: A definition of normal and altered function. Neurosurgery, 6, 675, 1980.
39. Pardridge, W. M., Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Disc., 1, 131, 2002.
40. Schinkel, A. H., The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol., 8, 161, 1997.
41. Litman, T., et al., From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci., 58, 931, 2001.
42. Müller, M., 48 human ATP-binding cassette transporters. http://www.nutrigene.4t.com/humanabc.htm, 2001.
43. Borst, P., and Oude Elferink, R., Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 71, 537, 2002.
44. Thiebaut, F., et al., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U S A, 84, 7735, 1987.
45. Cordon-Cardo, C., et al., Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U S A, 86, 695, 1989.
46. Kusuhara, H., Suzuki, H., and Sugiyama, Y., The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci., 87, 1025, 1998.
47. Di Pietro, A., et al., Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell. Mol. Life Sci., 59, 307, 2002.
48. Boumendjel, A., et al., Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev., 22, 512, 2002.
49. Cisternino, S., et al., Expression, up-regulation, and transport activity of the multidrug-resistance protein ABCG2 at the mouse blood-brain barrier. Cancer Res., 64, 3296, 2004.
50. Lee, Y. J., et al., Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: A minor role of breast cancer resistance protein. J. Pharmacol. Exp. Ther., 312, 44, 2005.
51. Cooray, H. C., et al., Localisation of breast cancer resistance protein in microvessel endothelium of human brain. NeuroReport, 13, 2059, 2002.
52. Jacquemin, E., et al., Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc. Natl. Acad. Sci. U S A, 91, 133, 1994.
53. Noe, I. B., et al., Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U S A, 94, 10346, 1997.
54. Abe, T., et al., Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J. Biol. Chem., 273, 22395, 1998.
55. Tamai, I., et al., Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun., 273, 251, 2000.
56. Hagenbuch, B., and Meier, P. J., Organic anion transporting polypeptides of the OATP/SLC21 family:Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch., 447, 653, 2004.
57. Wang, X., Wolkoff, A. W., and Morris, M. E., Flavonoids as a novel class of human organic aniontransporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos., 33, 1666, 2005.
58. Middleton, E. Jr., Kandaswami, C., and Theoharides, T. C., The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev., 52, 673, 2000.
59. Gledhill, J. R., et al., Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. U S A, 104, 13632, 2007.
60. Howitz, K. T., et al., Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191, 2003.
61. Youdim, K. A., et al., Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med., 36, 592, 2004.
62. Gescher, A. J., and Steward, W. P., Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomark. Prev., 12, 953, 2003.
63. Wenzel, E., et al., Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res., 49, 482, 2005.
64. Wenzel, E., and Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 49, 472, 2005.
65. Walle, T., et al., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 32, 1377, 2004.
66. Yu, C. W., et al., Human, rat, and mouse metabolism of resveratrol. Pharm. Res., 19, 1907, 2002.
67. Abd El Mohsen, M. M., et al., Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med., 33, 1693, 2002.
68. 3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis, 19, 1771, 1998.